z-logo
open-access-imgOpen Access
Present Situation and Progress of Pancreatic Cancer Radiotherapy
Author(s) -
Yu Gao,
Weigang Yan
Publication year - 2017
Publication title -
advanced emergency medicine
Language(s) - English
Resource type - Journals
ISSN - 2315-456X
DOI - 10.18686/aem.v6.111
Subject(s) - pancreatic cancer , medicine , radiation therapy , gemcitabine , palliative treatment , survival rate , cancer , oncology , surgery
Purpose: The research purpose is to effectively improve treatment effect of postoperative pancreatic cancer. Approaches: Adjuvant radiotherapy and chemotherapy; Palliative radiotherapy is adpoted for patients whose pancreatic cancer cannot be removed through excision. Comprehensive treatment approach is adopted where gemcitabine is added during radiotherapy. Result: The treatment effect of palliative operation is a little bit better than the traditional operative treatment, adoption of comprehensive treatment is obviously superior to the aforesaid two treatment approaches. Conculsion: Comprehensive treatment effectively improves survival rate of patients, and the survival time is greatly extended. Operation is generally adopted for pancreatic cancer treatment, but the effect is unsatisfactory. The average lifetime of patients after palliative operation treatment is only 5 to 76 months, and the survival rate after five years only reaches 8% to 15%, while the curative effect of radical resection is a little bit better, but the survival rate after five years also only reaches 12% to 24%, and the average lifetime is about 10 to 19 months. In recent years, with gradual progress of medical treatment level, clinical cases of adopting radiotherapy for pancreatic cancer are increasing, but its main effect is palliative or auxiliary. This article refers to plenty of documentation, makes thorough study of present situation and progress of pancreatic cancer radiotherapy, put forward its own suggestions and opinions, and have certain reference value.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here